Cargando…
Tolerability of Omalizumab in Asthma as a Major Compliance Factor: 10-Year Follow Up
BACKGROUND: There is a lack of data related to real life, long-term safety, tolerability and compliance of omalizumab treatment in asthma patients beyond 6 years. AIM: Study aimed to assess safety, tolerability, compliance and all reasons for treatment discontinuation during 10 years on omalizumab....
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Republic of Macedonia
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236047/ https://www.ncbi.nlm.nih.gov/pubmed/30455759 http://dx.doi.org/10.3889/oamjms.2018.394 |